摘要:
The invention relates to a combined analgesic pharmaceutical composition which comprises as component: A) (1R,2S,4R)-(−)-2-[N,N-(dimethylaminoethoxy)]-2-phenyl-1,7-7-trimethylbicyclo[2.2.1]heptane or a pharmaceutically acceptable acid addition salt thereof and as component B) morphine, an opioide type analgesic and/or a non-opioide type analgesic in admixture with suitable pharmaceutical carriers and/or auxiliary agents. Deramciclane increases the analgesic effect of morphine.
摘要:
The present invention is related to new 3,3-disubstituted indol-2-one derivatives of the general Formula (I). The new compounds are useful for the treatment or prophylaxis of the central nervous system, the gastrointestinal system or the cardiovascular system.
摘要:
The present invention is concerned with new 3,3-disubstituted indol-2-one derivatives of the general Formula (I), wherein R1 stands for hydrogen, halogen, alkyl having 1-7 carbon atom(s) or sulfonamido; R2 represents hydrogen or halogen; R3 denotes hydrogen, alkyl having 1-7 carbon atom(s) optionally carrying an aryl substituent or aryl optionally carrying one or two halogen substituent(s); R4 stands for alkyl having 1-7 carbon atom(s); R5 represents a group of the general Formula (II a) or (II b), wherein Q and W each represents nitrogen or CH; R6, R7 and R8 each stands for hydrogen, halogen, trifluoromethyl, alkyl or alkoxy having 1-7 carbon atom(s), or R6 and R7 together represent ethylenedioxy; m is 0, 1, or 2; a is a single, double or triple bond; n is 0, 1 or 2; and pharmaceutically acceptable acid addition salts thereof which are useful in the treatment or prophylaxis of diseases of the central nervous system, the gastrointestinal system and the cardiovascular system.
摘要翻译:本发明涉及通式(I)的新的3,3-二取代吲哚-2-酮衍生物,其中R 1代表氢,卤素,具有1-7个碳原子的烷基( s)或磺酰胺基; R 2表示氢或卤素; R 3表示氢,具有1-7个碳原子的烷基,任选地带有芳基取代基或任选地带有一个或两个卤素取代基的芳基; R 4代表具有1-7个碳原子的烷基; R 5表示通式(IIa)或(IIb)的基团,其中Q和W各自表示氮或CH; R 6,R 7和R 8均代表氢,卤素,三氟甲基,具有1-7个碳原子的烷基或烷氧基, ,或R 6和R 7一起代表亚乙二氧基; m为0,1或2; a是单,双或三键; n为0,1或2; 和其药学上可接受的酸加成盐,其可用于治疗或预防中枢神经系统疾病,胃肠系统和心血管系统。
摘要:
The present invention is concerned with new indol-2-one derivatives of the general Formula (I). The new compounds are useful for the treatment or prevention of the disorders of the central nervous system or the cardiovascular system.
摘要:
This invention relates to new oxaindene derivatives, a process for the preparation thereof and pharmaceutical compositions comprising the same. The compounds according to the invention are characterized by the general formula (1) ##STR1## wherein R.sup.1 represents lower C.sub.1-4 alkyl, lower C.sub.1-4 alkoxy or lower C.sub.3-6 cycloalkyl, R.sup.2 stands for hydrogen, lower C.sub.1-4 alkyl or lower C.sub.3-6 cycloalkyl, R.sup.3 stands for hydrogen, lower C.sub.1-4 alkyl, lower C.sub.1-4 alkoxy or benzyloxy, X denotes hydrogen, an aliphatic C.sub.1-4 -acyl or benzoyl or naphthoyl group, optionally substituted by 1 or more nitro or C.sub.1-4 -alkoxy group(s) or a group of the formula R.sup.5 R.sup.6 N--R.sup.7 --, wherein R.sup.7 represents lower C.sub.1-4 alkylene and R.sup.5 and R.sup.6 each represent lower C.sub.1-4 alkyl, or R.sup.5 and R.sup.6 together with the nitrogen atom to which they are attached form a piperidyl or morpholinyl group, A and B together form an ethylene or a vinylene group, and n is 1, 2 or 3, and have a strong 5-lipoxygenase (5-LO) enzyme inhibiting activity.
摘要:
The present invention is concerned with new indol-2-one derivatives of Formula (I), which have favourable activity profile for the prophylaxis and treatment of disorders in the central nervous or in the cadiovascular system.
摘要:
The present invention is concerned with new 3,3-disubstituted indol-2-one derivatives of the general Formula (I). Compounds according to the invention are useful for the prophylaxis or treatment of the disorders of the central nervous system.
摘要:
The invention relates to new 2,3-benzodiazepine derivatives of general Formula (I), (wherein R1 stands for methyl, formyl, carboxy, cyano, —CH═NOH, —CH═NNHCONH2 or —NR5R6, wherein R5 and R6 independently from each other represent hydrogen or lower alkyl or together with the nitrogen atom, they are attached to, form a 5- or 6-membered, saturated or unsaturated heterocyclic ring optionally containing one or more further nitrogen, sulfur and/or oxygen atom(s); R2 is nitro or amino; R3 stands for hydrogen, lower alkanoyl or CO—NR7R8, wherein R7 and R8 independently from each other stand for hydrogen, lower alkoxy, lower alkyl or lower cycloalkyl or together with the nitrogen atom, they are attached to, form a 5- or 6-membered, saturated or unsaturated heterocyclic ring optionally containing one or more further nitrogen, sulfur and/or oxygen atom(s); R4 is hydrogen or lower alkyl; the dotted lines have the following meaning: if R3 and R4 are not present, the bond between positions C8 and C9 is a single bond and the bond between positions C8 and N7 is a double bond; if R3 and R4 are present, the bonds between positions C8 and C9 and between position C8 and N7 are single bonds; and if R3 is present and R4 is missing, the bond between positions C8 and C9 is a double bond and the bond between positions C8 and N7 is a single bond) and salts thereof. The invention compounds have neuroprotective effect.
摘要:
The invention relates to new 8-chloro-2,3-benzodiazepine derivatives of the general formula (I), wherein R stands for a lower alkyl group or a group of the general formula —NH—R′, wherein R′ stands for a lower alkyl or a lower cycloalkyl group), and pharmaceutically acceptable acid addition salts thereof. The invention also encompasses a process for the preparation of said compounds, pharmaceutical compositions containing them and new intermediates useful for the preparation of the new 8-chloro-2,3-benzodiazepine derivatives. The compounds according to the invention possess AMPA/kainate receptor inhibiting activity.
摘要:
The invention relates to new 8-chloro-2,3-benzodiazepine derivatives of the general formula (I), wherein R stands for a lower alkyl group or a group of the general formula —NH—R′, wherein R′ stands for a lower alkyl or a lower cycloalkyl group), and pharmaceutically acceptable acid addition salts thereof. The invention also encompasses a process for the preparation of said compounds, pharmaceutical compositions containing them and new intermediates useful for the preparation of the new 8-chloro-2,3-benzodiazepine derivatives. The compounds according to the invention possess AMPA/kainate receptor inhibiting activity.